Teva
Flawed studies at Semler Research Centre calls for suspension of medicines, EMA recommends
July 25, 2016Manufacturing and Production, Sales and Marketing EMA, Novartis, Teva, manufacturing, semler
Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …
Teva sells $15 billion in bonds to fund Allergan generics deal
July 19, 2016Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics
Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …
Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports
July 15, 2016Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million
June 29, 2016Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition
Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …
Impax to acquire Teva, Allergan generic drugs for $586 million
June 22, 2016Research and Development, Sales and Marketing Allergan, Impax, Teva, generics
Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …
Teva returns rights to heart cell therapy to Mesoblast
June 16, 2016Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III
Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …
FDA asks Teva for further study on Huntington drug candidate
June 1, 2016Medical Communications, Research and Development Huntington disease, Teva, US FDA, regulation
Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) said the US regulators have put on hold the approval for its drug to …
Takeda, Teva name Hiroshi Matsumori CEO of Japanese generic drug joint venture
April 4, 2016Business Services, Sales and Marketing CEO Appointment, Takeda, Teva, joint venture
Japanese drug firm Takeda (TYO: 4502) and Israel-based Teva (NYSE: TEVA) named Hiroshi Matsumori the chief executive for their newly-formed …
Teva announces FDA approval for asthma injection, Cinqair
March 24, 2016Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair
The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …
Teva says closing buy of Allergan’s generics biz may take longer
March 16, 2016Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva
Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …
Teva funds research to protect fertility in women diagnosed with cancer
March 11, 2016Business Services, Research and Development Cancer, IVF Worldwide, Teva, fertility, radiotherapy
Israeli generics giant Teva has announced it will support IVF-Worldwide with a research grant to improve knowledge of fertility preservation …
FDA grants approval for first generic version of Viagra
March 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing FDA, Pfizer, Teva, erectile dysfunction, generic, viagra
The US Food and Drug Administration (FDA) has granted approval to the first generic version of Pfizer’s blockbuster erectile dysfunction …
Teva issues US recall of amikacin sulfate injection due to glass identified in vials
March 10, 2016Manufacturing and Production Teva, amikacin sulfate, glass, recall
Teva Pharmaceuticals has announced a voluntary recall of one lot of amikacin sulfate injection USP vials due to the potential …
Teva suffers EpiPen generic setback after FDA rejection
March 4, 2016Medical Communications, Research and Development FDA, Teva, analphylaxis, approval, auto injector, auto-injector, rejection
The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after …
Sanofi plans R&D jobs cuts in France
February 3, 2016Manufacturing and Production, Research and Development Sanofi, Teva, cuts, job losses, olivier brandicourt, redundancies
Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across the firm’s base in France, …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
AI: an early warning system for patient safety
Highlighting the value of lab research for healthcare innovation
